Arca
Skip to content

Narcolepsy

Drug research and approvals for narcolepsy: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 16, 2026, 34 studies of narcolepsy are recruiting on ClinicalTrials.gov, Health Canada has authorized 22 drug trials for it since 2013, FDA has 13 approved and 7 open orphan designations naming it, and the EU has 3 authorised medicines for it.

  • Recruiting worldwide: 34
  • Trials authorized in Canada: 22
  • FDA orphan approvals: 13
  • EU medicines: 3

Recruiting Now

Newest start dates first, of 34 recruiting on ClinicalTrials.gov ↗

Trials Authorized in Canada

The 10 newest of 22; search them all in Canada trials
Sep 4, 2026A randomized, double-blind, 3-arm parallel design study to investigate the efficacy, safety, tolerability, and pharmacokinetics of cleminorexton compared with…CLEMINOREXTON (ORX750)CENTESSA PHARMACEUTICALS (UK) LIMITEDPending
Jul 28, 2026An open-label, long-term extension study to investigate the safety, tolerability, and durability of treatment effect of alks 2680 in participants with…ALIXOREXTON (ALKS 2680)AlkermesPending
May 12, 2026A phase 3, randomized, double-blind, placebo-controlled, efficacy and safety study of hbs-301 in participants with narcolepsy followed by an open-label…PITOLISANT (HBS-301)HARMONY BIOSCIENCES MANAGEMENT, INC.Ongoing
May 7, 2026A phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of alks 2680 in adults with narcolepsy type 1ALIXOREXTON (ALKS 2680)AlkermesOngoing
Mar 19, 2026A phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of alks 2680 in adults with narcolepsy type 2ALIXOREXTON (ALKS 2680)AlkermesOngoing
Mar 12, 2026A phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of alks 2680 in adults with narcolepsy type 1ALIXOREXTON (ALKS 2680)AlkermesOngoing
Jan 16, 2026A randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of e2086 in adults with narcolepsyLEDASOREXTON (E2086)EisaiOngoing
Nov 28, 2025A long-term extension study of the safety and efficacy of cleminorexton in participants with narcolepsy and idiopathic hypersomnia who completed a sponsored…CLEMINOREXTON (ORX750)CENTESSA PHARMACEUTICALS (UK) LIMITEDOngoing
Feb 21, 2025A phase 2a, randomized, double-blind, placebo controlled study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of orx750 in subjects with…CLEMINOREXTON (ORX750)CENTESSA PHARMACEUTICALS (UK) LIMITEDOngoing
Aug 14, 2024A long-term extension study to evaluate the safety and tolerability of tak-861 in participants with selected central hypersomnia conditionsOVEPOREXTON (TAK-861)Takeda Pharmaceuticals USAOngoing

FDA Orphan Designations

Approved first, then open designations, newest first; 15 of 20
Nov 12, 2026Orzeyfultreatment of narcolepsy type 1 (narcolepsy with cataplexy) in adult patientsTakeda Pharmaceuticals U.S.A., Inc.Approved
Feb 13, 2026Wakixtreatment of excessive daytime sleepiness (EDS) or cataplexy in patients 6 years of age and older with narcolepsyHarmony Biosciences Management, Inc.Approved
Oct 16, 2024Lumryztreatment of cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsyFlamel Ireland Limited dba Avadel IrelandApproved
Jun 21, 2024Wakixtreatment of excessive daytime sleepiness (EDS) or cataplexy in adult patients with narcolepsy and treatment of EDS in pediatric patients 6…Harmony Biosciences Management, Inc.Approved
May 1, 2023LumryzTreatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsyFlamel Ireland Limited dba Avadel IrelandApproved
Oct 13, 2020WAKIX®treatment of excessive daytime sleepiness (EDS) or cataplexy in adult patients with narcolepsyHarmony Biosciences Management, Inc.Approved
Jul 21, 2020XywavXYWAV is indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with…Jazz Pharmaceuticals Ireland LimitedApproved
Aug 14, 2019WAKIXWAKIX is indicated for the treatment of excessive daytime sleepiness (EDS) in adult patients with narcolepsyHarmony Biosciences Management, Inc.Approved
Jun 17, 2019SunosiSUNOSI is indicated to improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsyAxsome Malta, Ltd.Approved
Oct 26, 2018XyremXyrem is indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with…Jazz Pharmaceuticals Ireland LimitedApproved
Nov 18, 2005XyremTreatment of excessive daytime sleepiness in patients with narcolepsyJazz Pharmaceuticals Ireland LimitedApproved
Jul 17, 2002XyremTreatment of cataplexy associated with narcolepsyJazz Pharmaceuticals Ireland LimitedApproved
Dec 24, 1998ProvigilImprove wakefulness in patients with excessive daytime sleepiness associated with narcolepsy.Cephalon, Inc.Approved
Jun 12, 20194-((L-valyl)oxy)butanoic acidTreatment of NarcolepsyAvadel CNS Pharmaceuticals, LLCDesignated
Oct 15, 2018reboxetineTreatment of narcolepsyAxsome Therapeutics, Inc.Designated

Medicines Authorised in the EU

Newest first
Jan 16, 2020SunosisolriamfetolAtnahs Pharma Netherlands B.V.EMA ↗
Mar 31, 2016Wakixpitolisant · orphanBioprojet PharmaEMA ↗
Oct 13, 2005Xyremsodium oxybateUCB Pharma LtdEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.